An observational study of direct oral anticoagulant awareness indicating inadequate recognition with potential for patient harm

A. Olaiya, B. Lurie, B. Watt, L. McDonald, M. Greaves, H. G. Watson*

*Corresponding author for this work

    Research output: Contribution to journalArticle

    11 Citations (Scopus)

    Abstract

    Background: Lack of awareness of the nature of the direct oral anticoagulants (DOACs) combined with the poor correlation between routine coagulation test prolongation and the activity of these drugs represents a potential for patient harm. Objectives: To establish the level of awareness of the different DOACs, and to assess whether prescribers were able to recognize the state of anticoagulation in a hypothetical patient. Methods and results: An electronic questionnaire was sent by email to prescribers in our health board. Among 143 respondents, we found significant differences in awareness of the currently licensed drugs. Of the respondents, 88%, 80% and 50%, respectively, recognized rivaroxaban, dabigatran, and apixaban. When provided with a routine clinical situation, only 13.5%, 17.5% and 16.8%, respectively, recognized that the hypothetical patient was anticoagulated, and only 55-58% recognized that it was unsafe to proceed with an invasive procedure. Conclusion: These results indicate a significant risk for patient harm related to lack of knowledge about this new group of frequently used drugs, and indicate that additional education and training on this subject are required.

    Original languageEnglish
    Pages (from-to)987-990
    Number of pages4
    JournalJournal of Thrombosis and Haemostasis
    Volume14
    Issue number5
    Early online date10 Feb 2016
    DOIs
    Publication statusPublished - May 2016

    Keywords

    • anticoagulants
    • apixaban
    • dabigatran
    • rivaroxaban
    • safety
    • factor XA inhibitor
    • coagulation assays
    • invasive procedures
    • liver-disease
    • routine

    Cite this

    An observational study of direct oral anticoagulant awareness indicating inadequate recognition with potential for patient harm. / Olaiya, A.; Lurie, B.; Watt, B.; McDonald, L.; Greaves, M.; Watson, H. G.

    In: Journal of Thrombosis and Haemostasis, Vol. 14, No. 5, 05.2016, p. 987-990.

    Research output: Contribution to journalArticle

    Olaiya, A. ; Lurie, B. ; Watt, B. ; McDonald, L. ; Greaves, M. ; Watson, H. G. / An observational study of direct oral anticoagulant awareness indicating inadequate recognition with potential for patient harm. In: Journal of Thrombosis and Haemostasis. 2016 ; Vol. 14, No. 5. pp. 987-990.
    @article{e000e1061534433e9cfc06b3d1af443f,
    title = "An observational study of direct oral anticoagulant awareness indicating inadequate recognition with potential for patient harm",
    abstract = "Background: Lack of awareness of the nature of the direct oral anticoagulants (DOACs) combined with the poor correlation between routine coagulation test prolongation and the activity of these drugs represents a potential for patient harm. Objectives: To establish the level of awareness of the different DOACs, and to assess whether prescribers were able to recognize the state of anticoagulation in a hypothetical patient. Methods and results: An electronic questionnaire was sent by email to prescribers in our health board. Among 143 respondents, we found significant differences in awareness of the currently licensed drugs. Of the respondents, 88{\%}, 80{\%} and 50{\%}, respectively, recognized rivaroxaban, dabigatran, and apixaban. When provided with a routine clinical situation, only 13.5{\%}, 17.5{\%} and 16.8{\%}, respectively, recognized that the hypothetical patient was anticoagulated, and only 55-58{\%} recognized that it was unsafe to proceed with an invasive procedure. Conclusion: These results indicate a significant risk for patient harm related to lack of knowledge about this new group of frequently used drugs, and indicate that additional education and training on this subject are required.",
    keywords = "anticoagulants, apixaban, dabigatran, rivaroxaban, safety, factor XA inhibitor, coagulation assays, invasive procedures, liver-disease, routine",
    author = "A. Olaiya and B. Lurie and B. Watt and L. McDonald and M. Greaves and Watson, {H. G.}",
    note = "Disclosure of Conflict of Interests M. Greaves has advised pharmaceutical companies in relation to their products, including antithrombotics. Other than travel expenses, this work was unpaid. The other authors state that they no conflict of interest.",
    year = "2016",
    month = "5",
    doi = "10.1111/jth.13288",
    language = "English",
    volume = "14",
    pages = "987--990",
    journal = "Journal of Thrombosis and Haemostasis",
    issn = "1538-7933",
    publisher = "Wiley-Blackwell",
    number = "5",

    }

    TY - JOUR

    T1 - An observational study of direct oral anticoagulant awareness indicating inadequate recognition with potential for patient harm

    AU - Olaiya, A.

    AU - Lurie, B.

    AU - Watt, B.

    AU - McDonald, L.

    AU - Greaves, M.

    AU - Watson, H. G.

    N1 - Disclosure of Conflict of Interests M. Greaves has advised pharmaceutical companies in relation to their products, including antithrombotics. Other than travel expenses, this work was unpaid. The other authors state that they no conflict of interest.

    PY - 2016/5

    Y1 - 2016/5

    N2 - Background: Lack of awareness of the nature of the direct oral anticoagulants (DOACs) combined with the poor correlation between routine coagulation test prolongation and the activity of these drugs represents a potential for patient harm. Objectives: To establish the level of awareness of the different DOACs, and to assess whether prescribers were able to recognize the state of anticoagulation in a hypothetical patient. Methods and results: An electronic questionnaire was sent by email to prescribers in our health board. Among 143 respondents, we found significant differences in awareness of the currently licensed drugs. Of the respondents, 88%, 80% and 50%, respectively, recognized rivaroxaban, dabigatran, and apixaban. When provided with a routine clinical situation, only 13.5%, 17.5% and 16.8%, respectively, recognized that the hypothetical patient was anticoagulated, and only 55-58% recognized that it was unsafe to proceed with an invasive procedure. Conclusion: These results indicate a significant risk for patient harm related to lack of knowledge about this new group of frequently used drugs, and indicate that additional education and training on this subject are required.

    AB - Background: Lack of awareness of the nature of the direct oral anticoagulants (DOACs) combined with the poor correlation between routine coagulation test prolongation and the activity of these drugs represents a potential for patient harm. Objectives: To establish the level of awareness of the different DOACs, and to assess whether prescribers were able to recognize the state of anticoagulation in a hypothetical patient. Methods and results: An electronic questionnaire was sent by email to prescribers in our health board. Among 143 respondents, we found significant differences in awareness of the currently licensed drugs. Of the respondents, 88%, 80% and 50%, respectively, recognized rivaroxaban, dabigatran, and apixaban. When provided with a routine clinical situation, only 13.5%, 17.5% and 16.8%, respectively, recognized that the hypothetical patient was anticoagulated, and only 55-58% recognized that it was unsafe to proceed with an invasive procedure. Conclusion: These results indicate a significant risk for patient harm related to lack of knowledge about this new group of frequently used drugs, and indicate that additional education and training on this subject are required.

    KW - anticoagulants

    KW - apixaban

    KW - dabigatran

    KW - rivaroxaban

    KW - safety

    KW - factor XA inhibitor

    KW - coagulation assays

    KW - invasive procedures

    KW - liver-disease

    KW - routine

    U2 - 10.1111/jth.13288

    DO - 10.1111/jth.13288

    M3 - Article

    VL - 14

    SP - 987

    EP - 990

    JO - Journal of Thrombosis and Haemostasis

    JF - Journal of Thrombosis and Haemostasis

    SN - 1538-7933

    IS - 5

    ER -